OLR1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, and specifically in CML, one study of nilotinib-treated patients found that those who harbored a polymorphism in the lectin-like oxidized LDL receptor gene LOX1 were at higher risk of developing a CVE (86% with polymorphism had a CVE vs. 35% without LOX1 polymorphism), presumably due to an induced inflammatory state (atherogenesis) [36].